table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
remdesivir GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ...

0 studies excluded by filtering options 0

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons